<!DOCTYPE html><html xmlns="http://www.w3.org/1999/xhtml"><head><title>Ace Exam</title><meta name="generator" content="Hovercraft! 1.0 http://regebro.github.com/hovercraft"></meta><meta name="author" content="Bas Rustenburg"></meta><meta name="description" content="Admission to candidacy exam"></meta><meta name="keywords" content="exam, ace, phd"></meta><link rel="stylesheet" href="css/hovercraft.css" media="all"></link><link rel="stylesheet" href="css/impressConsole.css" media="all"></link><link rel="stylesheet" href="css/highlight.css" media="all"></link><link rel="stylesheet" href="ace.css" media="screen,projection"></link></head><body class="impress-not-supported"><div id="impress" data-transition-duration="1"><div class="step" step="0" id="title" data-x="0" data-y="0"><h1 id="admission-to-candidacy-exam">Admission to candidacy exam</h1><h2 id="bas-rustenburg">Bas Rustenburg</h2><h3 id="date-5-29">Date : 5/29</h3><img src="images/background.png" alt="" width="800px" height=""></img></div><div class="step" step="1" data-x="1600" data-y="0"><h1 id="the-efficiency-of-the-pharmaceutical-industry-has-been-declining-for-years">The efficiency of the pharmaceutical industry has been declining for years</h1><h2 id="eroom-s-law">Eroom's law</h2><img src="images/erooms.jpg" alt="" width="500px" height=""></img>Kack W. Scannell et al. <em>Nature Reviews Drug Discovery</em> 11, 191-200 (March 2012)</div><div class="step" step="2" data-x="3200" data-y="0"><h1 id="it-takes-up-to-4-million-dollars-just-to-find-a-molecule-that-binds-a-target">It takes up to 4 million dollars, just to find a molecule that binds a target!</h1><img src="images/drug_disc.jpg" alt="" width="600px" height=""></img>Allen D. Roses  <em>Nature Reviews Drug Discovery</em> 7, 807-817 (October 2008)<p>Each consecutive step only gets more expensive!</p></div><div class="step" step="3" data-x="4800" data-y="0"><h1 id="there-is-a-clear-need-for-a-cheaper-strategy">There is a clear need for a cheaper strategy</h1><h2 id="computational-approaches-offer-a-cheap-solution">Computational approaches offer a cheap solution</h2><ul><li>They benefit from Moore's law, with increased computational efficiency each year</li><li>Drugs that do not bind the intended target can fail earlier, without a huge R&amp;D investment</li><li>Allows for a <em>fail fast, fail cheaply</em> methodology for designing drugs</li></ul><div class="notes"><p>For instance,
* compounds that have not been synthesized.
* when protein is expensive.
* When you cant reach concentrations of poorly soluble drugs.</p></div></div><div class="step" step="4" data-x="6400" data-y="0"><h1 id="it-is-all-about-the-binding-affinity">It is all about the binding affinity</h1><img src="images/colored_PL.png" alt="" width="300px" height=""></img></div><div class="step" step="5" data-x="8000" data-y="0"><h1 id="id1">It is all about the binding affinity</h1><table cellpadding="0" cellspacing="0"><tbody><tr><td><img src="images/colored_PL.png" alt="" width="300px" height=""></img></td></tr><tr><td><img src="images/colored_Kd_PL.png" alt="" width="300px" height=""></img></td></tr></tbody></table></div><div class="step" step="6" id="docking" data-x="9600" data-y="0"><h1 id="docking-does-not-provide-accurate-estimates">Docking does not provide accurate estimates</h1><img src="images/docking.png" alt="" width="600px" height=""></img><em>For prediction of compound affinity, none of the docking programs or scoring functions made
a useful prediction of ligand binding affinity.</em><p>Warren et al. J. Med. Chem., 2006, 49 (20), pp 5912&#x2013;5931</p></div><div class="step" step="7" id="deshaw" data-x="11200" data-y="0"><h1 id="if-your-name-is-de-shaw">If your name is DE Shaw</h1><h2 id="you-can-simulate-binding-events-from-microsecond-timescale-md-simulations">You can simulate binding events from microsecond timescale MD simulations</h2><img src="images/deshaw2.gif" alt="" width="" height=""></img><p>For typical drug off-rates (1/10 000 seconds), trajectories would need to be impractically long (hours), requiring ~100 million CPU-years to simulate.</p></div><div class="step" step="8" id="alchemical" data-x="12800" data-y="0"><h1 id="alchemical-free-energy-calculations">Alchemical free energy calculations</h1><h2 id="why">Why?</h2><p>They allow efficient sampling of the relevant states of protein-ligand complexes.</p><img src="images/colored_PL.png" alt="" width="300px" height=""></img><p>www.alchemistry.org</p></div><div class="step" step="9" data-x="14400" data-y="0"><h1 id="id2">Alchemical free energy calculations</h1><h2 id="in-principle-allow-for-us-to-calculate-affinities-directly">(in principle) allow for us to calculate affinities directly.</h2><img src="images/colored_Kd.png" alt="" width="300px" height=""></img></div><div class="step" step="10" data-x="16000" data-y="0"><h1 id="id3">Alchemical free energy calculations</h1><p>There are deficiencies that need to be addressed before alchemical free energy calculations can be applied widely.</p></div><div class="step" step="11" id="spec-aims" data-x="17600" data-y="0"><h1 id="id4">Alchemical free energy calculations</h1><p>There are deficiencies that need to be addressed before alchemical free energy calculations can be applied widely.</p><img src="images/alchem_aims_red.png" alt="" width="800px" height=""></img></div><div class="step" step="12" data-x="19200" data-y="0"><h1 id="id5">Alchemical free energy calculations</h1><p>There are deficiencies that need to be addressed before alchemical free energy calculations can be applied widely.</p><img src="images/alchem_aims_charge.png" alt="" width="800px" height=""></img></div><div class="step" step="13" data-x="20800" data-y="0"><h1 id="charged-ligands-include">Charged ligands include</h1><table cellpadding="0" cellspacing="0"><tbody><tr><td><img src="images/saquinavir.png" alt="" width="" height="200px"></img>Saquinavir</td><td rowspan="2"><img src="images/nelfinavir.png" alt="" width="" height="400px"></img>Nelfinavir</td></tr><tr><td><img src="images/indinavir.png" alt="" width="" height="200px"></img>Indinavir</td></tr></tbody></table><p>Protease inhibitors typically have positive charges. Here are three FDA approved <em>HIV-protease inhibitors</em>.</p><p>(image source: www.chemicalize.org)</p></div><div class="step" step="14" data-x="22400" data-y="0"><h1 id="id6">Charged ligands include</h1><table cellpadding="0" cellspacing="0"><tbody><tr><td><img src="images/aspirin.png" alt="" width="" height="350px"></img>Aspirin</td><td><img src="images/ibuprofen.png" alt="" width="" height="350px"></img><p>Ibuprofen</p></td></tr></tbody></table><p>Many over-the-counter <em>nonsteroidal anti-inflammatory drugs</em> have charged moieties!</p><p>(image source: www.chemicalize.org)</p></div><div class="step" step="15" data-x="24000" data-y="0"><h1 id="id7">Charged ligands include</h1><h2 id="anti-histamines">Anti-histamines</h2><table cellpadding="0" cellspacing="0"><tbody><tr><td><img src="images/histamine.png" alt="" width="200px" height=""></img>Histamine</td></tr></tbody></table><p>(image source: www.chemicalize.org)</p></div><div class="step" step="16" data-x="25600" data-y="0"><h1 id="id8">Charged ligands include</h1><h2 id="id9">Anti-histamines</h2><table cellpadding="0" cellspacing="0"><tbody><tr><td><img src="images/diphenhydramine.png" alt="" width="250px" height=""></img>Benadryl (diphenhydramine)</td><td><img src="images/clemastine.png" alt="" width="200px" height=""></img>Tavist (clemastine)</td></tr><tr><td><img src="images/azelastine.png" alt="" width="200px" height=""></img>Astelin (azelastine)</td><td><img src="images/hydroxyzine.png" alt="" width="350px" height=""></img>Atarax (hydroxyzine)</td></tr></tbody></table><p>(image source: www.chemicalize.org)</p></div><div class="step" step="17" data-x="27200" data-y="0"><h1 id="id10">Alchemical free energy calculations</h1><p>There are deficiencies that need to be addressed before alchemical free energy calculations can be applied widely.</p><img src="images/alchem_aims_protonation.png" alt="" width="800px" height=""></img></div><div class="step" step="18" data-x="28800" data-y="0"><h1 id="protonation-states-may-vary-for-kinase-inhibitors">Protonation states may vary for kinase inhibitors</h1><h2 id="egfr-inhibitors-lapatinib-and-gefitinib">EGFR inhibitors lapatinib and gefitinib</h2><table cellpadding="0" cellspacing="0"><tbody><tr><td><img src="images/lapatinib.png" alt="" width="300px" height=""></img>Lapatinib</td><td><img src="images/gefitinib.png" alt="" width="300px" height=""></img>Gefitinib</td></tr></tbody></table><p>Many FDA approved kinase inhibitors have titratable moieties with pKas near 7.</p><p>(image source: www.chemicalize.org)</p><div class="notes"><p>These two drugs are EGFR/Her2 inhibitors, important in lung and breast cancers
(Non small cell lung cancer)</p></div></div><div class="step" step="19" data-x="30400" data-y="0"><h1 id="id11">Protonation states may vary for kinase inhibitors</h1><h2 id="imatinib-a-potent-inhibitor-of-abl-kinase">Imatinib, a potent inhibitor of Abl kinase</h2><img src="images/imatinib_image_curve.png" alt="" width="550px" height=""></img><p>Szak&#xE1;cs, Z. et al. <em>J Med Chem</em> 2005, 48, 249&#x2013;255</p><div class="notes"><p>Do not forget to mention that the protonated form of these inhibitors is charged</p></div></div><div class="step" step="20" data-x="32000" data-y="0"><h1 id="id12">Alchemical free energy calculations</h1><p>There are deficiencies that need to be addressed before alchemical free energy calculations can be applied widely.</p><img src="images/alchem_aims_multi.png" alt="" width="800px" height=""></img></div><div class="step" step="21" data-x="33600" data-y="0"><h1 id="binding-of-multiple-ligands-to-a-single-target">Binding of multiple ligands to a single target</h1><img src="images/HSA.png" alt="" width="600px" height=""></img>A summary of human serum albumin (HSA) crystal structures bound to small molecules.<p>Ghuman, J et al. <em>J Mol Biol</em> 2005, 353, 38&#x2013;52</p></div><div class="step" step="22" data-x="35200" data-y="0"><h1 id="id13">Binding of multiple ligands to a single target</h1><img src="images/HSA_drugsites.png" alt="" width="600px" height=""></img>A summary of human serum albumin (HSA) crystal structures bound to small molecules.<p>Ghuman, J et al. <em>J Mol Biol</em> 2005, 353, 38&#x2013;52</p></div><div class="step" step="23" data-x="36800" data-y="0"><h1 id="id14">Binding of multiple ligands to a single target</h1><h2 id="human-serum-albumin">Human serum albumin</h2><img src="images/HSA_extrasites.png" alt="" width="600px" height=""></img>A summary of human serum albumin (HSA) crystal structures bound to small molecules.<p>Ghuman, J et al. <em>J Mol Biol</em> 2005, 353, 38&#x2013;52</p></div><div class="step" step="24" data-x="38400" data-y="0"><h1 id="id15">Binding of multiple ligands to a single target</h1><h2 id="fragment-based-drug-discovery">Fragment based drug discovery</h2><h3 id="at-high-concentrations-multiple-fragments-can-bind-to-a-protein">At high concentrations, multiple fragments can bind to a protein</h3><p>The binding of 3 fragments to p38a kinase.</p><table cellpadding="0" cellspacing="0"><tbody><tr><td><img src="images/fragment_p38_4ehv.png" alt="" width="400px" height=""></img>PDB: 4EHV</td><td><img src="images/fragment_4ehv.png" alt="" width="200px" height=""></img>PDB: 0SJ</td></tr></tbody></table><p>Over B et al. <em>Nat Chem</em> 2013 Jan;5(1):21-8</p></div><div class="step" step="25" id="aim1" data-x="40000" data-y="0"><h1 id="establish-a-correct-quantitative-treatment-of-alchemical-free-energy-calculations-for-binding-of-charged-ligands">Establish a correct quantitative treatment of alchemical free energy calculations for binding of charged ligands</h1><h2 id="aim-1">Aim 1.</h2><img src="images/alchem_aims_charge.png" alt="" width="800px" height=""></img></div><div class="step" step="26" data-x="41600" data-y="0"><h1 id="experiment-versus-computation">Experiment versus computation</h1><ul><li>We will use <em>alchemical free energy calculations</em> to predict binding free energies, while we compare various approaches to each other</li><li>At the same time, we will perform <em>isothermal titration calorimetry</em> (ITC) experiments that can validate the different corrections.</li></ul></div><div class="step" step="27" id="aim1-modelsystem" data-x="43200" data-y="0"><h1 id="the-host-guest-model-system">The host-guest model system</h1><h2 id="id16">Aim 1</h2><p>We will use cucurbit-[7]-uril as a model system</p><table cellpadding="0" cellspacing="0"><tbody><tr><td><img src="images/guest11_top.png" alt="" width="200px" height=""></img></td><td><img src="images/guest11_side.png" alt="" width="200px" height=""></img></td><td rowspan="2"><p>The system is useful because:</p><ul><li>Both guest and hosts are very soluble</li><li>They are small, with few degrees of freedom</li><li>The affinities are in the range of typical protein-small molecule interactions</li></ul></td></tr><tr><td colspan="2"><img src="images/Kd_guest2.png" alt="" width="410px" height=""></img></td></tr></tbody></table></div><div class="step" step="28" data-x="44800" data-y="0"><h1 id="basic-slide-on-itc">Basic slide on ITC</h1></div><div class="step" step="29" data-x="46400" data-y="0"><h1 id="current-itc-analysis-protocols-do-not-propagate-errors-of-the-experimental-procedure">Current ITC analysis protocols do not propagate errors of the experimental procedure</h1><img src="images/abrf_mirg.png" alt="" width="600px" height=""></img>Myszka DG et al. <em>J Biomol Tech</em> 2003 Dec; 14(4):247-69</div><div class="step" step="30" data-x="48000" data-y="0"><h1 id="observed-errors-can-directly-be-correlated-to-errors-in-concentration">Observed errors can directly be correlated to errors in concentration</h1><p>The extinction coefficient</p><img src="images/extinction_mirg.png" alt="" width="400px" height=""></img><dl><dt>From the lambert beer law:</dt><dd><img src="images/colored_extinction.png" alt="" width="150px" height=""></img>where A is absorbance, c is concentration and l is the pathlength</dd></dl></div><div class="step" step="31" id="aim1-motivation" data-x="49600" data-y="0"><h1 id="id17">Establish a correct quantitative treatment of alchemical free energy calculations for binding of charged ligands</h1><h2 id="id18">Aim 1.</h2><table cellpadding="0" cellspacing="0"><tbody><tr><td><img src="images/reif_oostenbrink.png" alt="" width="" height=""></img></td><td rowspan="2"><p>In order to apply alchemical free energy calculations to charged ligands, one needs to eliminate artifacts introduced into the calculation arising from the modeling of bulk solvent behavior using a small periodic system.</p><p>Ligand interactions with:</p><ul><li>solvent (Blue)</li><li>receptor (Red)</li><li>self-interaction (Green)</li></ul></td></tr><tr><td><p>Image Source: <a class="footnoteref" id="footnote-backref-id19" href="#footnote-id20">[1]</a></p></td></tr></tbody></table><div class="footnote" id="footnote-id20"><a class="footnotereturn" href="#footnote-backref-id19" title="return to content">#1: </a><p>MM Reif and C Oostenbrink. J Comput Chem 35.3 (Nov. 2013), pp. 227&#x2013;243</p></div></div><div class="step" step="32" id="aim1-approx" data-x="51200" data-y="0"><h1 id="id21">Establish a correct quantitative treatment of alchemical free energy calculations for binding of charged ligands</h1><h2 id="id22">Aim 1.</h2><table cellpadding="0" cellspacing="0"><tbody><tr><td><img src="images/reif_oostenbrink.png" alt="" width="" height=""></img></td><td rowspan="2"><p>Bulk liquids are approximated in simulation, either by using periodic boundary conditions, or an implicit solvent.
Often, to further reduce computation cost, we introduce truncated,potentials and non-Coulombic electrostatics (such as particle mesh Ewald,[PME],and reaction field [RF] potentials).</p></td></tr><tr><td><p>Image Source: <a class="footnoteref" id="footnote-backref-id23" href="#footnote-id24">[2]</a></p></td></tr></tbody></table><div class="footnote" id="footnote-id24"><a class="footnotereturn" href="#footnote-backref-id23" title="return to content">#2: </a><p>MM Reif and C Oostenbrink. J Comput Chem 35.3 (Nov. 2013), pp. 227&#x2013;243</p></div></div><div class="step" step="33" id="aim1-corrections" data-x="52800" data-y="0"><h1 id="id25">Establish a correct quantitative treatment of alchemical free energy calculations for binding of charged ligands</h1><h2 id="id26">Aim 1.</h2><dl><dt>A number of corrections have been proposed but:</dt><dd><ul><li>They have not been compared to each other</li><li>Quantitative correctness of these methods has not been established</li></ul></dd><dt>Sources:</dt><dd><ul><li>MM Reif and C Oostenbrink. J Comput Chem 35.3 (Nov. 2013), pp. 227&#x2013;243</li><li>GJ Rocklin et al. J Chem Phys 139.18 (2013), p. 184103.</li><li>YL Lin et al.  J Chem Theory Comput 10.7 (July 2014), pp. 2690&#x2013;2709.</li></ul></dd></dl></div><div class="step" step="34" id="aim1-subaims" data-x="54400" data-y="0"><h1 id="id27">Establish a correct quantitative treatment of alchemical free energy calculations for binding of charged ligands</h1><h2 id="id28">Aim 1.</h2><h3 id="subaim-1-1-develop-an-accurate-approach-to-quantifying-experimental-uncertainty-in-itc-using-bayesian-inference">Subaim 1.1:  Develop an accurate approach to quantifying experimental uncertainty in ITC using Bayesian inference.</h3><p>Because we need a reliable experimental dataset in order to make a quantitative comparison</p><h3 id="subaim-1-2-perform-a-quantitative-comparison-of-suggested-correction-models-to-experiments-to-establish-a-correct-treatment-of-charged-ligands-in-alchemical-free-energy-calculations">Subaim 1.2: Perform a quantitative comparison of suggested correction models to experiments to establish a correct treatment of charged ligands in alchemical free energy calculations.</h3><p>Evaluating the charge corrections, testing an alternative (counter ions), comparing to each other and experiment</p></div><div class="step" step="35" id="aim1-bitc" data-x="56000" data-y="0"><h1 id="develop-an-accurate-approach-to-quantifying-experimental-uncertainty-in-itc-using-bayesian-inference">Develop an accurate approach to quantifying experimental uncertainty in ITC using Bayesian inference.</h1><h2 id="subaim-1-1">Subaim 1.1</h2><p>The experimental parameters, <img src="images/colored_theta.png" alt="lt_theta" width="" height=""></img> , can be estimated using Bayes rule:
<img src="images/colored_bayes_rule.png" alt="lt_Bayes" width="" height=""></img> , where</p><blockquote><ul><li><img src="images/colored_posterior.png" alt="lt_posterior" width="" height=""></img> is the posterior distribution. The probability of the parameters given the observed data. <em>This is what we want to know!</em></li><li><img src="images/colored_likelihood.png" alt="lt_likelihood" width="" height=""></img> is the likelihood. The probability of the observed data, given a single set of parameters.</li><li><img src="images/colored_prior.png" alt="lt_prior" width="" height=""></img> are distributions containing prior information. We can use this to propagate errors.</li></ul></blockquote><p>We can sample from the posterior distribution by using a technique called <em>Markov chain Monte Carlo</em>.</p></div><div class="step" step="36" id="aim1-mcmc" data-x="57600" data-y="0"><h1 id="sampling-from-a-posterior-distribution-using-mcmc">Sampling from a posterior distribution using MCMC</h1><p>Flipping an weighted coin</p><img src="images/distributions.png" alt="" width="" height=""></img><a href="http://bayesianbiologist.com">http://bayesianbiologist.com</a></div><div class="step" step="37" id="aim1-parameters" data-x="59200" data-y="0"><h1 id="id29">Develop an accurate approach to quantifying experimental uncertainty in ITC using Bayesian inference.</h1><h2 id="id30">Subaim 1.1</h2><h3 id="the-itc-model-structure">The ITC model structure</h3><img src="images/colored_parameters.png" alt="" width="" height=""></img><p>Thermodynamic parameters include</p><blockquote><ul><li>binding affinity, <img src="images/colored_dG.png" alt="lt_dG" width="" height=""></img></li><li>enthalpy of binding, <img src="images/colored_dH.png" alt="lt_dH" width="" height=""></img></li><li>mechanical heats offset, <img src="images/colored_H0.png" alt="lt_H0" width="" height=""></img></li><li>concentration of syringe component, <img src="images/colored_Xs.png" alt="lt_Xs" width="" height=""></img></li><li>concentration of cell component, <img src="images/colored_Mc.png" alt="lt_Mc" width="" height=""></img></li><li>noise parameter, <img src="images/colored_sigma.png" alt="lt_sigma" width="" height=""></img></li></ul></blockquote><p>We can use prior distributions <img src="images/colored_prior.png" alt="lt_prior" width="" height=""></img> to propagate error estimates in concentrations, and include previous measurements.</p></div><div class="step" step="38" id="aim1-likelihood" data-x="60800" data-y="0"><h1 id="id31">Develop an accurate approach to quantifying experimental uncertainty in ITC using Bayesian inference.</h1><h2 id="id32">Subaim 1.1</h2><h3 id="id33">The ITC model structure</h3><table cellpadding="0" cellspacing="0"><tbody><tr><td><p>The likelihood model, <img src="images/colored_likelihood.png" alt="lt_likelihood" width="" height=""></img>, is defined as</p><img src="images/colored_model.png" alt="" width="" height=""></img></td><td><img src="images/normal.png" alt="" width="" height="350px"></img></td></tr><tr><td colspan="2"><p>Where the observed heats are sampled from a normal distribution <img src="images/colored_norm_n.png" alt="lt_norm" width="" height=""></img>, with a variance of <img src="images/colored_variance.png" alt="lt_variance" width="" height=""></img>.</p></td></tr></tbody></table></div><div class="step" step="39" data-x="62400" data-y="0"><h1 id="what-will-our-experimental-results-look-like">What will our experimental results look like?</h1><table cellpadding="0" cellspacing="0"><tbody><tr><td><img src="images/itcexp.png" alt="" width="400px" height=""></img></td><td><img src="images/postpredictive.png" alt="" width="400px" height=""></img></td></tr></tbody></table></div><div class="step" step="40" id="aim1-correction-models" data-x="64000" data-y="0"><h1 id="compare-the-different-charge-correction-models">Compare the different charge correction models</h1><h2 id="subaim-1-2">Subaim 1.2</h2><p>We will consider these approaches:</p><ul><li>Reif and Oostenbrink use thermodynamic cycles to eliminate individual components</li><li>Rocklin et al. use Poisson-Boltzmann calculations with exact either numerical solutions to quantify the erroneous contributions.</li><li>Lin et al. use potential of mean force (PMF) calculations in a large simulation system, pulling the ligand away from the protein non-alchemically.</li><li>Eliminating a pair of ions, with a net charge of 0.</li></ul><p>We will first check if the methods produce the same quantitative estimate.
Next, we will compare to experiment, to see if they produce a quantitatively correct answer.</p><p>This is the first comparison of any of these methods on the same system!</p></div><div class="step" step="41" data-x="65600" data-y="0"><h1 id="backup-slides-on-individual-corrections">(Backup) Slides on individual corrections</h1></div><div class="step" step="42" id="aim1-python" data-x="67200" data-y="0"><pre class="highlight code python"><span class="k">class</span> <span class="nc">VPITC</span><span class="p">(</span><span class="n">Instrument</span><span class="p">):</span>

   <span class="sd">"""
   The MicroCal VP-ITC.
   Volumes from brochure used. http://www.malvern.com/Assets/MRK2058.pdf
   If possible, we recommend using the calibrated volume for the .itc file.
   """</span>

   <span class="k">def</span> <span class="nf">__init__</span><span class="p">(</span><span class="bp">self</span><span class="p">):</span>
       <span class="nb">super</span><span class="p">(</span><span class="n">VPITC</span><span class="p">,</span> <span class="bp">self</span><span class="p">)</span><span class="o">.</span><span class="n">__init__</span><span class="p">(</span><span class="n">V0</span><span class="o">=</span><span class="mf">1.400</span> <span class="o">*</span> <span class="n">ureg</span><span class="o">.</span><span class="n">milliliter</span><span class="p">,</span> <span class="n">V_correction</span><span class="o">=</span><span class="mf">0.044</span> <span class="o">*</span> <span class="n">ureg</span><span class="o">.</span><span class="n">milliliter</span><span class="p">,</span> <span class="n">itcfile</span><span class="o">=</span><span class="bp">None</span><span class="p">,</span> <span class="n">description</span><span class="o">=</span><span class="s">"MicroCal VP-iTC"</span><span class="p">)</span></pre></div><div class="step" step="43" id="aim2" data-x="68800" data-y="0"><h1 id="quantify-the-magnitude-of-protonation-state-effects-on-binding">Quantify the magnitude of protonation state effects on binding</h1><h2 id="aim-2">Aim 2.</h2><img src="images/imatinib_sites.png" alt="" width="600px" height=""></img></div><div class="step" step="44" id="aim2-intro" data-x="70400" data-y="0"><h1 id="id34">Quantify the magnitude of protonation state effects on binding</h1><h2 id="id35">Aim 2.</h2><p>Proteins and many small-molecule drugs contain titratable moieties that can change protonation state upon binding or sample mixtures of protonation states, often in a conformation-dependent manner.</p><img src="images/protonation.png" alt="" width="700px" height=""></img><em>The pH dependent effect in lin-benzoguanines binding to tRNA&#x2212;guanine transglycosylase</em> <a class="footnoteref" id="footnote-backref-id36" href="#footnote-id37">[3]</a><div class="footnote" id="footnote-id37"><a class="footnotereturn" href="#footnote-backref-id36" title="return to content">#3: </a><p>Chasing Protons: .... ,  Neeb et al. <em>J. Med. Chem.</em>, 2014, 57 (13), pp 5554&#x2013;5565</p></div></div><div class="step" step="45" id="aim2-kinase" data-x="72000" data-y="0"><h1 id="protonation-states-are-relevant-to-kinase-inhibitors">Protonation states are relevant to kinase inhibitors</h1><ul><li>Kinases are hugely important targetsfor anti cancer drugs.</li><li>Evidence exists that for the binding of imatinib to Abl kinase, pH dependent effects may contribute to the binding affinity, and preliminary data indicates that it is the same for <em>many other kinase inhibitors</em>.</li></ul><table cellpadding="0" cellspacing="0"><tbody><tr><td><img src="images/inhibitor-pKas.png" alt="" width="300px" height=""></img></td><td><img src="images/imatinib_image_curve.png" alt="" width="300px" height=""></img></td></tr></tbody></table></div><div class="step" step="46" id="aim2-subaims" data-x="73600" data-y="0"><h1 id="id38">Quantify the magnitude of protonation state effects on binding</h1><h2 id="id39">Aim 2.</h2><h3 id="subaim-2-1-benchmark-small-molecule-pka-prediction-tools-against-experimental-data-for-kinase-inhibitors">Subaim 2.1: Benchmark small molecule pKa prediction tools against experimental data for kinase inhibitors.</h3><p>We need reliable pKa estimates of small molecule kinase inhibitors. We will benchmark available tools and compare to experimental data.</p><h3 id="subaim-2-2-survey-the-kinase-inhibitor-cocrystal-structures-for-possible-protonation-state-effects-in-inhibitor-binding">Subaim 2.2: Survey the kinase:inhibitor cocrystal structures for possible protonation state effects in inhibitor binding.</h3><p>We will identify kinase-inhibitor systems that show changes in the populations of protonation states from MCCE calculations.</p><h3 id="subaim-2-3-dissect-the-determinants-and-impact-of-protonation-state-effects-on-binding-affinity-through-free-energy-calculations-and-itc-experiments">Subaim 2.3: Dissect the determinants and impact of protonation state effects on binding affinity through free energy calculations and ITC experiments.</h3><p>The systems identified will be simulated using alchemical free energy calculations, and we will perform ITC experiments on them.</p></div><div class="step" step="47" id="subaim-2.1" data-x="75200" data-y="0"><h1 id="benchmark-small-molecule-pka-prediction-tools-against-experimental-data-for-kinase-inhibitors">Benchmark small molecule pKa prediction tools against experimental data for kinase inhibitors.</h1><h2 id="subaim-2-1">Subaim 2.1</h2></div><div class="step" step="48" data-x="76800" data-y="0"><h1 id="experimental-data">Experimental data</h1><p>** Add image T3 data &amp; instrument **</p><p>For the sake of having a completely computational framework to perform these calculations, we would like to find a reliable predictor.</p></div><div class="step" step="49" data-x="78400" data-y="0"><h1 id="we-will-benchmark-small-molecule-pka-prediction-tools-against-this-data">We will benchmark small molecule pKa prediction tools against this data.</h1><ul><li><strong>MoKa</strong> generates pKa s based on atomistic descriptors, defined by the surrounding atoms. The descriptors are based on molecular interaction fields calculated using GRID for a library of 3D fragments, but can successfully be applied on 2D structures.</li><li>Schrodinger&#x2019;s <strong>Jaguar</strong> provides means of estimating pKa values using quantum mechanical methods.</li><li><strong>Epik</strong> uses Hammett Taft linear free energy approaches [86] for predicting pKa values.</li></ul></div><div class="step" step="50" data-x="80000" data-y="0"><h1 id="identify-kinase-systems-where-protonation-state-changes-could-be-important">Identify kinase systems where protonation state changes could be important.</h1></div><div class="step" step="51" id="subaim-2.2" data-x="81600" data-y="0"><h1 id="survey-the-kinase-inhibitor-cocrystal-structures-for-possible-protonation-state-effects-in-inhibitor-binding">Survey the kinase:inhibitor cocrystal structures for possible protonation state effects in inhibitor binding.</h1><h2 id="subaim-2-2">Subaim 2.2</h2><p>We will investigate complex structures from the protein databank, using a framework called MCCE.</p><img src="images/imatinib_sites.png" alt="" width="600px" height=""></img></div><div class="step" step="52" data-x="83200" data-y="0"><h1 id="id40">Survey the kinase:inhibitor cocrystal structures for possible protonation state effects in inhibitor binding.</h1><p>MCCE samples multiple conformations of protein side-chains and estimates the most probably protonation state.
The framework has been extended to incorporate sampling of ligands. We will keep ligand conformations fixed to those found in crystal structures.</p><h2 id="id41">Subaim 2.2</h2><img src="images/mcce2_sharp.png" alt="" width="400px" height=""></img></div><div class="step" step="53" id="subaim-2.3" data-x="84800" data-y="0"><h1 id="dissect-the-determinants-and-impact-of-protonation-state-effects-on-binding-affinity-through-free-energy-calculations-and-itc-experiments">Dissect the determinants and impact of protonation state effects on binding affinity through free energy calculations and ITC experiments.</h1><h2 id="subaim-2-3">Subaim 2.3</h2><p>We will perform alchemical free energy calculations using a dynamic protonation state scheme also known as <em>constant-pH</em> simulations.</p><p>These calculations will use the pKa predictions provided by our pKa tool of choice.</p><div class="notes"><p>Or our experimental estimates, if the pKa tools dont perform well enough.</p></div><p>We will quantify</p><blockquote><ul><li>The total free energy of binding and,</li><li>The contribution of protonation state changes to the total.</li><li>Perform complementary ITC experiments to validate the free energy calculations</li></ul></blockquote></div><div class="step" step="54" data-x="86400" data-y="0"><h1 id="constant-ph-alchemical-free-energy-calculations">Constant-pH alchemical free energy calculations</h1></div><div class="step" step="55" data-x="88000" data-y="0"><h1 id="calculating-free-energy-of-protonation-contribution">Calculating free energy of protonation contribution</h1></div><div class="step" step="56" data-x="89600" data-y="0"><h1 id="itc-experiments-to-disseminate-protonation-state-effects-from-binding">ITC experiments to disseminate protonation state effects from binding</h1><h2 id="using-buffers-with-different-ionization-enthalpy">Using buffers with different ionization enthalpy</h2><p>In order to detect protonation state effects in ITC, we can perform multiple experiments that have different <em>ionization enthalpies</em>.
This will lead to different magnitude contributions to the binding affinity, which will allow us to detect and quantify net protonation state effects.</p></div><div class="step" step="57" data-x="91200" data-y="0"><h1 id="alternatives">Alternatives</h1></div><div class="step" step="58" data-x="92800" data-y="0"><h1 id="develop-a-framework-for-alchemical-free-energy-calculations-to-describe-weak-association-and-cooperative-ligand-binding">Develop a framework for alchemical free energy calculations to describe weak association and cooperative ligand binding.</h1><h2 id="aim-3">Aim 3.</h2><p>Weak binding and association of multiple ligands to proteins are ubiquitous interactions in biological and pharmaceutically relevant systems.</p><p>It is particularly common when using drug discovery approaches such as fragment-based ligand design, where concentrations are scaled up to detect weak binding signals, often resulting in multiple associating fragments.</p><p>Most available free energy calculation frameworks focus on 1:1 binding interactions, and are not suited for calculating free energies of an arbitrary number of ligands.</p><p><strong>We will overcome deficiencies in current frameworks with a new framework that can provide predictions for ligands binding multiple times to a single macromolecule.</strong></p></div><div class="step" step="59" data-x="94400" data-y="0"><h1 id="id42">Develop a framework for alchemical free energy calculations to describe weak association and cooperative ligand binding.</h1><h2 id="id43">Aim 3.</h2><h3 id="subaim-3-1-extend-alchemical-free-energy-calculations-to-simulate-multiple-ligand-binding">Subaim 3.1: Extend alchemical free energy calculations to simulate multiple ligand binding.</h3><p>Current frameworks are focussed on single ligand (1:1) association to proteins</p><h3 id="subaim-3-2-validate-computational-predictions-by-applying-bayesian-model-selection-on-itc-experiments-of-hsa-and-a-series-of-nsaids">Subaim 3.2: Validate computational predictions by applying Bayesian model selection on ITC  experiments of HSA and a series of NSAIDs.</h3><p>We will expand the Bayesian ITC framework (Aim 1) to incorporate multiple ligand binding.</p></div><div class="step" step="60" data-x="96000" data-y="0"><h1 id="an-alchemical-ladder-between-stoichiometric-states">An alchemical ladder between stoichiometric states</h1><img src="images/latex_images/equil_ladder.png" alt="" width="600px" height=""></img></div><div class="step" step="61" data-x="97600" data-y="0"><h1 id="extend-alchemical-free-energy-calculations-to-simulate-multiple-ligand-binding">Extend alchemical free energy calculations to simulate multiple ligand binding.</h1><h2 id="subaim-3-1">Subaim 3.1</h2></div><div class="step" step="62" id="subaim3.2" data-x="99200" data-y="0"><h1 id="validate-computational-predictions-by-applying-bayesian-model-selection-on-itc-experiments-of-hsa-and-a-series-of-nsaids">Validate computational predictions by applying Bayesian model selection on ITC  experiments of HSA and a series of NSAIDs.</h1><h2 id="subaim-3-2">Subaim 3.2</h2></div><div class="step" step="63" data-x="100800" data-y="0"><h1 id="that-s-all-folks">That's all folks!</h1></div></div><div id="hovercraft-help"><table><tr><th>Space</th><td>Forward</td></tr><tr><th>Left, Down, Page Down</th><td>Next slide</td></tr><tr><th>Right, Up, Page Up</th><td>Previous slide</td></tr><tr><th>P</th><td>Open presenter console</td></tr><tr><th>H</th><td>Toggle this help</td></tr></table></div><script type="text/javascript" src="js/impress.js"></script><script type="text/javascript" src="js/impressConsole.js"></script><script type="text/javascript" src="js/hovercraft.js"></script></body></html>